Annegret Van der Aa

2.0k citations

41 papers · 1.6k indexed · 1 hit paper · h-index 17

Rheumatology top 1%
Immunology top 5%
Oncology top 5%
Genetics top 5%
Hematology top 2%

Co-authors: Chantal Tasset Pille Harrison Frédéric Vanhoutte Florence Namour Maria Greenwald Mykola Stanislavchuk Séverine Vermeire René Westhovens
Topics: Chronic Lymphocytic Leukemia Research (18 papers)Rheumatoid Arthritis Research and Therapies (12 papers)Inflammatory Bowel Disease (11 papers)
Cited by: Rheumatology Hematology Genetics
Journals: The Lancet Journal of Clinical OncologySHILAP Revista de lepidopterología
Partner nations: Belgium United States United Kingdom

In The Last Decade

Annegret Van der Aa

40 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

2016 344 citations Séverine Vermeire, Stefan Schreiber et al. The Lancet profile →

Peers

Countries citing papers authored by Annegret Van der Aa

Since Specialization

Citations

This map shows the geographic impact of Annegret Van der Aa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annegret Van der Aa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annegret Van der Aa more than expected).

Fields of papers citing papers by Annegret Van der Aa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annegret Van der Aa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annegret Van der Aa. The network helps show where Annegret Van der Aa may publish in the future.

Co-authorship network of co-authors of Annegret Van der Aa

This figure shows the co-authorship network connecting the top 25 collaborators of Annegret Van der Aa. A scholar is included among the top collaborators of Annegret Van der Aa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annegret Van der Aa. Annegret Van der Aa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer 2023 ·The Oncologist ·(unknown),Matthew Krebs,Ruth Plummer,Filip De Vos,Eric Angevin,Hans Prenen,Martin Förster,Glen Clack,Annegret Van der Aa,Marc Tjwa,(unknown),Timothy Perera,Martijn P. Lolkema	1
2	Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials 2020 ·Rheumatology and Therapy ·Jacqueline M. Tarrant,René Galien,Wanying Li,Lovely Goyal,(unknown),Rachael E. Hawtin,Wangshu Zhang,Annegret Van der Aa,Peter C. Taylor	27
3	Response to Placebo, Measured by Endoscopic Evaluation of Crohn’s Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction Trials 2019 ·Clinical Gastroenterology and Hepatology ·Marjolijn Duijvestein,Jenny Jeyarajah,Leonardo Guizzetti,Guangyong Zou,Claire E. Parker,(unknown),Niels Vande Casteele,Reena Khanna,Annegret Van der Aa,William J. Sandborn,Brian G. Feagan,Geert D’Haens,Vipul Jairath	20
4	Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes 2018 ·Arthritis Research & Therapy ·Mark C. Genovese,René Westhovens,Luc Meuleners,Annegret Van der Aa,Pille Harrison,Chantal Tasset,Arthur Kavanaugh	44
5	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial 2018 ·The Lancet ·Philip J. Mease,Laura C. Coates,Philip Helliwell,Mykola Stanislavchuk,(unknown),Anna Dudek,Walid Abi‐Saab,Chantal Tasset,Luc Meuleners,Pille Harrison,R. Besuyen,Annegret Van der Aa,Neelufar Mozaffarian,Joy M. Greer,Rebecca Kunder,Filip Van den Bosch,Dafna D. Gladman	156
6	Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor 2018 ·British Journal of Clinical Pharmacology ·Florence Namour,(unknown),Annegret Van der Aa,Pille Harrison,Yan Xin,Chantal Tasset	21
7	THU0173 Long term safety and efficacy of filgotinib in a phase 2B open label extension study in patients with rheumatoid arthritis: results up to 144 weeks 2017 ·Annals of the Rheumatic Diseases ·Rieke Alten,René Westhovens,Arthur Kavanaugh,Mark C. Genovese,Kevin Winthrop,Maria Greenwald,(unknown),F J Enriquez,Mykola Stanislavchuk,Minodora Mazur,Alberto Spindler,Regina Cseuz,(unknown),(unknown),István Szombati,Anna Dudek,Luc Meuleners,Chantal Tasset,Pille Harrison,Annegret Van der Aa	3
8	Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2) 2016 ·Annals of the Rheumatic Diseases ·Arthur Kavanaugh,Joel M. Kremer,(unknown),Regina Cseuz,O. V. Reshetko,Mykola Stanislavchuk,Maria Greenwald,Annegret Van der Aa,Frédéric Vanhoutte,Chantal Tasset,Pille Harrison	176
9	A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies 2016 ·Investigational New Drugs ·Geert A. Cirkel,Bojana Milojkovic Kerklaan,Frédéric Vanhoutte,Annegret Van der Aa,Giocondo Lorenzon,Florence Namour,Philippe Pujuguet,(unknown),(unknown),Tom J. Snijders,Emile E. Voest,Jan H.M. Schellens,Martijn P. Lolkema	53
10	Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions 2016 ·Drug Metabolism Letters ·Florence Namour,Julie Desrivot,Annegret Van der Aa,Pille Harrison,Chantal Tasset,(unknown)	52
11	Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trialbreakdown → 2016 ·The Lancet ·Séverine Vermeire,Stefan Schreiber,Robert Petryka,Tanja Kuehbacher,Xavier Hébuterne,Xavier Roblin,Maria Kłopocka,Adrian Goldiș,Maria Wiśniewska‐Jarosińska,Andrey Baranovsky,Róbert Sike,(unknown),Chantal Tasset,Annegret Van der Aa,Pille Harrison	344
12	Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects 2016 ·British Journal of Clinical Pharmacology ·Florence Namour,René Galien,(unknown),Annegret Van der Aa,Frédéric Vanhoutte,Johan Beetens,(unknown)	47
13	Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1) 2016 ·Annals of the Rheumatic Diseases ·René Westhovens,Peter C. Taylor,Rieke Alten,(unknown),(unknown),Minodora Mazur,Maria Greenwald,Annegret Van der Aa,Frédéric Vanhoutte,Chantal Tasset,Pille Harrison	184
14	Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection 2015 ·Clinical Pharmacokinetics ·Florence Namour,Paul M. Diderichsen,Eugène Cox,Béatrice Vayssière,Annegret Van der Aa,Chantal Tasset,(unknown)	113
15	THU0229 Safety and Efficacy of GLPG0634, a Selective JAK1 Inhibitor in Patients with Rheumatoid Arthritis: Results of a 4-Week Phase II a Dose Ranging, Multi-Center Trial 2013 ·Annals of the Rheumatic Diseases ·Frédéric Vanhoutte,Annegret Van der Aa,Luc Meuleners,Gerben van ‘t Klooster	1
16	Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial 2012 ·Annals of the Rheumatic Diseases ·René Westhovens,Filip De Keyser,(unknown),Е. Л. Насонов,Johan Beetens,Annegret Van der Aa,Piet Wigerinck,Florence Namour,Frédéric Vanhoutte,Patrick Durez	18
17	A twelve-week exploratory phase II trial of GLPG0259 versus placebo in patients with active rheumatoid arthritis and inadequate response to methotrexate 2011 ·Ghent University Academic Bibliography (Ghent University) ·René Westhovens,Filip De Keyser,(unknown),Е. Л. Насонов,Johan Beetens,Annegret Van der Aa,Piet Wigerinck,Florence Namour,Frédéric Vanhoutte,Patrick Durez	1
18	46 A Phase 2a Randomized Placebo-Controlled Double-Blind Multi-Center Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011 in Patients With Moderately Active Ulcerative Colitis 2010 ·Gastroenterology ·Séverine Vermeire,Paul Rutgeerts,Geert D’Haens,Martine De Vos,Brian Bressler,Annegret Van der Aa,Bernard Coulie,Cindy J. Wong,Brian G. Feagan	15
19	T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study 2003 ·Clinical & Experimental Immunology ·Annegret Van der Aa,Niels Hellings,Robert Medaer,(unknown),Y Palmers,J. Raus,Piet Stinissen	43
20	Identification of overrepresented T cell receptor genes in blood and tissue biopsies by PCR-ELISA 1999 ·Journal of Immunological Methods ·(unknown),Annegret Van der Aa,Piet Geusens,Caroline Vandevyver,J. Raus,Piet Stinissen	16

About Annegret Van der Aa

Annegret Van der Aa is a scholar working on Genetics, Hematology and Rheumatology, having authored 41 papers that have together received 1.6k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (18 papers), Rheumatoid Arthritis Research and Therapies (12 papers) and Inflammatory Bowel Disease (11 papers). The work is most often cited by research in Rheumatology (697 citations), Hematology (402 citations) and Genetics (302 citations). Annegret Van der Aa has collaborated with scholars based in Belgium, United States and United Kingdom. Frequent co-authors include Chantal Tasset, Pille Harrison, Frédéric Vanhoutte, Florence Namour, Maria Greenwald, Mykola Stanislavchuk, Séverine Vermeire, René Westhovens, Minodora Mazur and Maria Kłopocka. Their work appears in journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact